Siegel™ Transcatheter Aortic Valve Replacement System (TAVR) Early Feasibility Study

NCT ID: NCT06680427

Last Updated: 2025-12-03

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-03-26
• Study Completion Date: 2025-12-31

Brief Summary

The Siegel™ Transcatheter Aortic Valve (TAVR) early feasibility study objective is to assess the acute and long-term safety and feasibility of the Siegel TAVR device in adult subjects with symptomatic, severe native aortic stenosis eligible for the transcatheter aortic valve replacement.

Detailed Description

The Siegel™ Transcatheter Aortic Valve (TAVR) Early Feasibility Study is a prospective, non-randomized, single-arm, multi-center study conducted in the US. The primary objective is to assess the acute and long-term safety and feasibility of the Siegel TAVR device in adult subjects with symptomatic, severe native aortic stenosis eligible for the transcatheter aortic valve replacement.

Conditions

Aortic Stenosis Symptomatic

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment Arm

Group Type: EXPERIMENTAL

Siegel Transcatheter Aortic Valve (TAVR)

Intervention Type: DEVICE

Replacement of native aortic valve with the Siegel Transcatheter Aortic Valve (TAVR) by a transfemoral approach.

Interventions

Siegel Transcatheter Aortic Valve (TAVR)

Replacement of native aortic valve with the Siegel Transcatheter Aortic Valve (TAVR) by a transfemoral approach.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

Subjects are eligible for entry in this study if all the following conditions are met:

1. Symptomatic, severe native aortic stenosis in subjects 50 years or older Aortic Valve Area (AVA) ≤ 1.0 cm2 or Aortic Valve Area (AVA) index ≤ 0.6 cm2/m2 and Jet velocity ≥ 4.0 m/s or mean gradient ≥ 40 mmHg or dimensionless Index <0.25

2. New York Heart Association Functional Class ≥ 2

3. Requires aortic valve replacement and is indicated for TAVR as determined by the Heart Team (composed of an experienced interventional cardiologist and an experienced cardiac surgeon)

4. Eligible for transfemoral delivery of the Siegel TAVR

5. Native aortic annulus suitable for safe placement of Siegel 23mm or 26mm transcatheter heart valve (preprocedural measurements by Transthoracic Echocardiogram (TTE) and Computed Tomography (CT) of area derived aortic annulus diameter)

6. Understands the study requirements and the treatment procedures and provides written informed consent

7. Subject agrees to complete all required scheduled follow-up visits.

Exclusion Criteria

Subjects will be excluded for entry in this study if any of the following conditions are met:

Anatomical

1. Anatomy precluding safe placement of Siegel TAVR

2. Iliofemoral vessel characteristics that would preclude safe placement of the introducer sheath.

3. Pre-existing prosthetic heart valve in any position (note, mitral ring is not an exclusion).

4. Unicuspid or bicuspid aortic valve

5. Severe aortic regurgitation (>3+)

6. Severe mitral or severe tricuspid regurgitation(>3+) requiring intervention.

7. Moderate to severe mitral stenosis.

8. Hypertrophic obstructive cardiomyopathy

9. Echocardiographic evidence of intracardiac mass, thrombus or vegetation requiring treatment.

10. Severe basal septal hypertrophy with outflow gradient Clinical

11. Evidence of an acute myocardial infarction ≤ 30 days before enrollment.

12. Any percutaneous coronary or peripheral interventional procedure performed within 30 days prior to the index procedure

13. Blood dyscrasias as defined: leukopenia (WBC < 3000 cell/mL, anemia (Hgb < 9 g/dL), thrombocytopenia (platelet count < 50,000 cells/mL), history of bleeding diathesis or coagulopathy.

14. Untreated clinically significant Coronary Artery Disease (CAD) requiring revascularization

15. Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or mechanical hemodynamic support within the past 30 days.

16. Hemodynamic or respiratory instability requiring inotropic support, mechanical ventilation or mechanical heart assistance within 30 days of enrollment

17. Need for emergency surgery for any reason

18. Ventricular dysfunction with left ventricular ejection fraction (LVEF) < 30% as measured by resting echocardiogram

19. Recent (within 6 months) cerebrovascular accident (CVA) or transient ischemic attack (TIA).

20. Symptomatic carotid or vertebral artery disease or successful treatment of carotid stenosis within 30 days of enrollment

21. Renal insufficiency (eGFR < 30 ml/min per the Cockcroft-Gault formula) and/or renal replacement therapy, or end stage renal disease requiring chronic dialysis

22. GI bleeding within the past 3 months

23. Severe lung disease with Forced Expiratory Volume in 1 second (FEV1) < 50% predicted or currently on home oxygen

24. History of cirrhosis or any active liver disease

25. Significant frailty as determined by the Heart Team (after objective assessment of frailty parameters).

26. Significant abdominal or thoracic aortic disease (such as porcelain aorta, abdominal aortic aneurysm > 5.0 cm, severe calcification, aortic coarctation, etc.) that would preclude safe passage of the delivery system or cannulation and aortotomy for surgical AVR .

27. Severe pulmonary hypertension (e.g., pulmonary artery systolic pressure ≥ 2/3 systemic pressure)

28. A known hypersensitivity or contraindication to any of the following which cannot be adequately pre-medicated: aspirin, heparin, molybdenum, rhenium, ticlopidine and clopidogrel, contrast media

29. Ongoing sepsis, including active endocarditis

30. Body Mass Index (BMI) > 50 kg/m2

31. Subject refuses a blood transfusion

32. Life expectancy < 24 months due to associated non-cardiac co-morbid conditions

33. Other medical, social, or psychological conditions that in the opinion of an Investigator precludes the subject from appropriate consent

34. Severe dementia (resulting in either inability to provide informed consent for the trial/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits)

35. Currently participating in an investigational drug or another investigational device trial

36. Subject is contraindicated for cardiac computed tomography (CT).

37. Subject belongs to a vulnerable population (Vulnerable subject populations are defined as individuals with mental disability, persons in nursing homes, children, impoverished persons, homeless persons, nomads, refugees, and those permanently incapable of giving informed consent. Vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces, and persons kept in detention).

• Minimum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

MiRus

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Cedars-Sinai Medical Center

Los Angeles, California, United States

Stanford

Palo Alto, California, United States

NCH Healthcare System

Naples, Florida, United States

Piedmont Healthcare

Atlanta, Georgia, United States

Mayo Clinic

Rochester, Minnesota, United States

Atlantic Health System

Morristown, New Jersey, United States

Columbia University Medical Center/ NYPH

New York, New York, United States

Cleveland Clinic

Cleveland, Ohio, United States

Countries

United States

Other Identifiers

MR-001

Identifier Type: -

Identifier Source: org_study_id